Physician profile
Bryan E Caudle
NPI 1992196349
$2,044.37
in general payments reported to CMS, 2019-2025
19 companies · $1,210 in 2025
The $1,210 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $35.16 · 2023: $179 · 2024: $621 · 2025: $1,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,009.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $561.61 | 2024-2025 | |
| Novo Nordisk INC | $394.16 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $141.88 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $139.42 | 2024-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $139.19 | 2023 | Venaseal |
| Pfizer INC. | $96.97 | 2025 | |
| Amgen INC. | $72.46 | 2024-2025 | Repatha, Tezspire, Otezla |
| Abbott Laboratories | $71.34 | 2024-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $69.06 | 2023-2025 | Airsupra, Farxiga |
| Viatris Specialty LLC | $54.51 | 2025 | Yupelri |
| Kyowa Kirin, INC. | $53.54 | 2025 | |
| Phathom Pharmaceuticals, INC. | $47.96 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $47.89 | 2025 | Rexulti |
| Lilly USA, LLC | $38.69 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $36.84 | 2022-2025 | Shingrix, Bexsero |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $32.69 | 2025 | Sublocade |
| Insulet Corporation | $18.39 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.19 | 2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.58 | 2025 | Ofev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Caudle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.